AS
Antonio Sarno
  • Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Norway
研究方向
  • Cancer biology
个人信息

Education

M.Sc. in Molecular Medicine, Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway , 2011

Current position

Doctoral candidate in Molecular Medicine, Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway

Publications

  1. Galashevskaya, A., Sarno, A., Vagbo, C. B., Aas, P. A., Hagen, L., Slupphaug, G. and Krokan, H. E. (2013). A robust, sensitive assay for genomic uracil determination by LC/MS/MS reveals lower levels than previously reported. DNA Repair (Amst) 12(9): 699-706.
  2. Sousa, M. M., Zub, K. A., Aas, P. A., Hanssen-Bauer, A., Demirovic, A., Sarno, A., Tian, E., Liabakk, N. B. and Slupphaug, G. (2013). An inverse switch in DNA base excision and strand break repair contributes to melphalan resistance in multiple myeloma cells. PLoS One 8(2): e55493.
  3. Doseth, B., Visnes, T., Wallenius, A., Ericsson, I., Sarno, A., Pettersen, H. S., Flatberg, A., Catterall, T., Slupphaug, G., Krokan, H. E. and Kavli, B. (2011). Uracil-DNA glycosylase in base excision repair and adaptive immunity: species differences between man and mouse. J Biol Chem 286(19): 16669-16680.
  4. Bhattacharya, N., Sarno, A., Idler, I. S., Fuhrer, M., Zenz, T., Dohner, H., Stilgenbauer, S. and Mertens, D. (2010). High-throughput detection of nuclear factor-kappaB activity using a sensitive oligo-based chemiluminescent enzyme-linked immunosorbent assay. Int J Cancer 127(2): 404-411.
  5. Zenz, T., Habe, S., Denzel, T., Mohr, J., Winkler, D., Buhler, A., Sarno, A., Groner, S., Mertens, D., Busch, R., Hallek, M., Dohner, H. and Stilgenbauer, S. (2009). Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood 114(13): 2589-2597.
  6. Zenz, T., Mohr, J., Edelmann, J., Sarno, A., Hoth, P., Heuberger, M., Helfrich, H., Mertens, D., Dohner, H. and Stilgenbauer, S. (2009). Treatment resistance in chronic lymphocytic leukemia: the role of the p53 pathway. Leuk Lymphoma 50(3): 510-513.